voluntarily open avenues for litigation by the consumer.
Nonetheless, just as business is now subject to increasingly severe and stringent governmental regulations and threats covering every aspect of its existence, medical practice will find itself burdened with legislative restrictions stratified to a point of obliterating some of the areas of freedom.
Suspicion bordering on paranoia is focussed on the delivery of health-care services at local, state, and national levels. Any seemingly unethical practice is immediately exposed by the press, and made subject to legislative harangue, with demands to protect the people, leading finally to restriction by laws and regulations.
The recent hearing on Lincomycin and Cleocin, with the subsequent revelation of the toxicities, are examples of what can happen to patients who are at the whims of practitioners writing indiscriminately for "multiple" and "new" drugs without being fully aware of their toxic manifestations.
The public-at-Iarge and those who are concerned about the proper delivery of health-care and the functioning of health care services cannot candidly stand by and allow these practices to go unchallenged. It is, therefore, necessary at this time for responsible practitioners in all facets of the Health Care Delivery System to rise up and do something to save the health care team from destruction. HUGH N. LUNAN, Pharm.D.
Assistant Clinical Professor and Clinical Coordinator College of Pharmacy and Pharmacol Sciences
Howard University, Washington, D.C. 20059 The Need for Pharmacokinetic Data in Diseased Individuals IT HAS ONLY BEEN IN FECENT YEARS THAT PHARMA-COKINETIC DATA has become readily available for many of the drugs being used today. At the present time, however, there are some drugs for which pharmacokinetic data has not been released, or is unknown. Even though the pharmacokinetic data that is available today is a step in the right direction, this is only a beginning for there is an immediate necessity for data dealing with the effects of disease states on drug pharmacokinetics. It is wellknown that various disease states, such as congestive heart failure, diabetes mellitus, cystic fibrosis, etc., significantly alter many of the patient's vital processes, but the relationships between drug pharmacokinetics and the disease state have not been adequately defined. While many investigators are looking at pharmacokinetic parameters in animals and normal human subjects, pharmacokinetic investigations in diseased individuals are not receiving the attention they need. The complete blame for a lack of clinical pharmacokinetic data is not to be put on the investigators in this area. Some of the pharmaceutical companies have thwarted responsible investigation in the area of drug-disease effects on pharmacokinetic parameters. These companies have claimed, for the most part, that they have established other priorities which make them unable to commit funds for support of the grants submitted to them dealing with drugdisease effects on pharmacokinetic parameters. Other companies have not as yet acted on grants submitted to them dealing with this subject.
It is my hope that this appeal will help stimulate pharmacokinetic research in the basic problem areas of drug-disease interactions. It is the responsibility of the pharmaceutical industry to provide pharmacokinetic data on drug products, not only in healthy individuals, but in diseased individuals as well. Once this data is obtained, health practitioners will be able to better understand the influence of diseases on drug pharmacokinetic parameters, and thus will be able to provide better and safer drug management of diseases. RANDALL A. PRINCE, Pharm.D.
Assistant Professor of Clinical Pharmacy School of Pharmacy West Virginia University Morgantown, West Virginia 26506
Wandering From
Bed to Bed
EIGHT YEARS AGO, I REMEMBER MY "WEEDS AND SEEDS"
professor announcing to us that the Dean had selected four senior students to make hospital rounds with physicians. She chuckled and predicted, "They sure are going to make fools of themselves." I don't know if those ill-prepared and professionally romantic students looked foolish or not. Yet in spite of what happened during those early experiments, ensuing years have found increasing numbers of students, hospital pharmacists, clinical faculty and, too rarely, pharmacy basic science professors and deans "wandering" around hospital wards. Throughout the nation, from community hospitals with private physicians to large teaching hospitals with medical students, interns, residents and attending physicians, pharmacists are attempting to become a member of the health care team on rounds.
As a student at the University of Southern California, as staff pharmacist at Long Beach Memorial Hospital and as a faculty member at both the University of Georgia and Iowa, I have been wandering from bed to bed with physicians for nearly six and one-half years. It has become dogma that rounding is an essential component of clinical pharmacy in the hospital environment. The question to be answered is who if anyone benefits from this time consuming ritual. The patient? The phar-
